PLRX

Rating neutralAI Memo

Pliant Therapeutics

As of 2026-07-11/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-11 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

FORTIFY enrollment and tolerability are the key 2026 execution checkpoint • 2026-12-31

Expected move: +30%

Biggest risk

The bear case is that PLRX is now largely a single-core-clinical-story oncology pivot after the 2025 bexotegrast/IPF termination, and current evidence is still early, non-pivotal, and vulnerable to enrollment, durability, and replication risk. [#PR-EARNINGS-2026-05-12]

Invalidation

Break below $1 or thesis failure.

What would change my mind?

The supported bull case is narrow: Pliant has runway into 2H 2028 and is advancing PLN-101095 after dosing the first FORTIFY participant, while Q1 materials described early anti-tumor activity and biomarker support in heavily pretreated solid tumors. [#PR-EARNINGS-2026-05-12][#SEC-8K-2026-05-11]

Research note

Recommendation

neutral

Confidence

medium

As of

2026-07-11

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Runway reduces immediate financing pressure
2027 interim FORTIFY data is still the main rerating test
The supported bull case is narrow: Pliant has runway into 2H 2028 and is advancing PLN-101095 after dosing the first FORTIFY participant, while Q1 materials described early anti-tumor activity and biomarker support in heavily pretreated solid tumors.

BearKey bullets

Despite runway into the second half of 2028, PLRX is still a sub-$100 million clinical-stage biotech and could face future financing or dilution pressure if development timelines extend.
Early PLN-101095 response signals may not replicate or deepen in FORTIFY expansion cohorts.
Enrollment or execution slippage in FORTIFY would weaken confidence in the oncology reset.

WatchKey bullets

FORTIFY enrollment and tolerability are the key 2026 execution checkpoint

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $2 (p=45%)

Bull/Bear spread: +126% / -48%

Vs latest close: Bull +126% · Base +30% · Bear -48%

Scenario probabilities

Bull Target: $3 (p=25%)Base Target: $2 (p=45%)Bear Target: $1 (p=30%)

Commentary

This remains a cautious monitoring setup. Primary company materials support the two most important positives: funded runway and active FORTIFY execution. However, the evidence set is still dominated by company filings and the May 11, 2026 earnings release, while verified analyst revision flow, usable social coverage, options context, and short-interest context are unavailable in the packet. The low $1.12 anchor versus the packet’s $2.5 median target suggests skepticism remains high, not that upside is validated.

As of 2026-07-11 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Runway reduces immediate financing pressure
2027 interim FORTIFY data is still the main rerating test

Scenarios

Bull Target (Scenario probability)

$3 / p=25% prob

Base Target (Scenario probability)

$2 / p=45% prob

Bear Target (Scenario probability)

$1 / p=30% prob

Price $1 as of 2026-07-17

Nearest Scenario: Base (∆ 30%)

Targets vs latest close: Bull +126% · Base +30% · Bear -48%

Sentiment & Exposure

News Sentiment (30d)

0.10

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
FORTIFY enrollment and tolerability are the key 2026 execution checkpoint
Company materials said FORTIFY is enrolling after first patient dosing in April, with NSCLC, clear cell renal cell carcinoma, and high-tumor-mutational-burden cohorts; clean execution would support the oncology pivot, while delays or weak early signals would hurt credibility. [#PR-EARNINGS-2026-05-12][#SEC-8K-2026-05-11]
Prob 57.00% • Move 14.00% • Priced-in 46.00%

Short-term Catalysts

Next few weeks

Runway reduces immediate financing pressure
2026-09-30
Pliant said it had $172.4 million of cash, cash equivalents and short-term investments as of March 31, 2026 and expects that balance to fund operations into the second half of 2028, which lowers near-term dilution pressure while the oncology reset is still early. [#PR-EARNINGS-2026-05-12][#SEC-8K-2026-05-11]
Prob 74% • Move 9% • Priced-in 72%

Long-term Catalysts

Months to a year

2027 interim FORTIFY data is still the main rerating test
2027-12-31
Pliant said interim FORTIFY data are expected in 2027, and its Q1 2026 release highlighted one confirmed complete response, two confirmed partial responses, and one unconfirmed partial response in the Phase 1 program; durability and replication in expansion cohorts remain the core upside test. [#PR-EARNINGS-2026-05-12]
Prob 33% • Move 42% • Priced-in 24%

Risks

Despite runway into the second half of 2028, PLRX is still a sub-$100 million clinical-stage biotech and could face future financing or dilution pressure if development timelines extend.
Early PLN-101095 response signals may not replicate or deepen in FORTIFY expansion cohorts.
Enrollment or execution slippage in FORTIFY would weaken confidence in the oncology reset.
Peer set and analyst coverage are thin, limiting external validation of the thesis and raising volatility around clinical updates.

Peers

Symbol	Summary
MNOV	Micro-cap biotech comparator useful mainly for funding and event-volatility context; packet support for direct mechanism or indication overlap is weak.
EDSA	Another small-cap biotech reference for financing and execution sensitivity, but not a close PLN-101095 therapeutic peer from the evidence provided.
IMA	Broad small-cap biotech comparator only; evidence does not show direct overlap in target biology, trial design, or indication mix.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-11

AI Stock Memo: PLRX - Pliant Therapeutics - RankAlpha